Physician profile
Steven P Carter
NPI 1770549248
$2,619.81
in general payments reported to CMS, 2019-2025
37 companies · $645 in 2025
The $645 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $147 · 2021: $462 · 2022: $620 · 2023: $296 · 2024: $225 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $823 · Education: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.96 |
| Education | $342.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $544.04 | 2019-2025 | Liletta |
| Astellas Pharma US INC | $270.11 | 2020-2025 | Veozah, Myrbetriq |
| Millicent US INC | $270.00 | 2025 | |
| Exeltis, USA INC. | $172.29 | 2022-2025 | Slynd |
| Aspira Women'S Health INC | $122.39 | 2022 | |
| Channel Medsystems, INC. | $108.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $107.10 | 2021 | |
| Pfizer INC. | $106.19 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $95.24 | 2024-2025 | |
| Hologic Sales and Service, LLC | $82.45 | 2019-2022 | |
| Organon LLC | $70.20 | 2021-2025 | Jada System, Nexplanon |
| Myovant Sciences INC. | $63.83 | 2021-2022 | |
| Daiichi Sankyo INC. | $51.13 | 2019-2021 | |
| Minerva Surgical, INC | $49.34 | 2022 | |
| Therapeuticsmd, INC. | $42.00 | 2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.